Tobin Schilke - 29 Feb 2024 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: CFO
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 29 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2024, 16:44:22 UTC
Previous filing: 02 Feb 2024
Next filing: 19 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Award	$0	+17,447	+9.3%	$0.000000	205,849	29 Feb 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 29, 2024, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2023 through December 31, 2023, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024.

Content

Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 29, 2024, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2023 through December 31, 2023, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024.